Celsion Corp. (CLSN) Rating Lowered to Hold at Maxim Group
Celsion Corp. (NASDAQ:CLSN) was downgraded by Maxim Group from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.
Shares of Celsion Corp. (NASDAQ:CLSN) opened at 0.865 on Thursday. The stock’s 50 day moving average is $1.09 and its 200-day moving average is $1.27. Celsion Corp. has a one year low of $0.85 and a one year high of $2.31. The stock’s market capitalization is $22.33 million.
Celsion Corp. (NASDAQ:CLSN) last released its earnings results on Monday, August 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.02. Celsion Corp. had a negative net margin of 4,390.50% and a negative return on equity of 139.38%. On average, equities research analysts predict that Celsion Corp. will post ($0.85) EPS for the current fiscal year.
A hedge fund recently raised its stake in Celsion Corp. stock. Sabby Management LLC raised its position in Celsion Corp. (NASDAQ:CLSN) by 7,986.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,519,365 shares of the company’s stock after buying an additional 1,500,576 shares during the period. Sabby Management LLC owned approximately 6.48% of Celsion Corp. worth $1,930,000 at the end of the most recent quarter. 15.05% of the stock is owned by institutional investors.
Celsion Corp. Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Stock Ratings for Celsion Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corp. and related stocks with our FREE daily email newsletter.